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ABSTRACT 
Bioanalysis most often requires an extraction procedure to isolate the target compounds 
from a complex matrix. The aim of this work was to evaluate microextraction in packed 
syringe (MEPS) performance as a sample preparation technique by developing new 
analytical methods for different categories of compounds utilizing MEPS in 
combination with LC-MS/MS. The overall goal was to provide high throughput 
methods that can offer automation, on-line coupling to mass spectrometry and short 
sample preparation time. 
 
MEPS is a new sample preparation method representing a miniaturization of solid 
phase extraction (SPE) technique that can be fully automated. Sample preparation is 
performed on the packed bed. Less sorbent material is used with MEPS; about 1 mg of 
sorbent is inserted into a syringe needle (100-250 µL) as a plug and thus less solvents 
are needed. Different categories of compounds have been used to evaluate the 
performance of MEPS on-line with LC and tandem mass spectrometry (MS/MS), 
cytostatic, local anaesthetics, immunosuppressive drugs and one anaesthetic. 
 
In study I, the first on-line quantification method for cyclophosphamide was developed 
and in study II it was the first quantification method for cyclophosphamide from whole 
blood. This method was applied to test tail vein sampling method from mice by 
studying the cyclophosphamide pharmacokinetic in mice. In study III, local 
anaesthetics were quantified from whole blood for the first time, using only 25 µL 
sample volume. In study IV an on-line method for immunosuppressive drugs was 
developed which can be implemented in clinical laboratories. Remifentanil in study V 
was quantified from whole blood utilizing only 20 µL sample volume which might 
facilitate pharmacokinetic studies on pediatric patients. 
 
Full method validation has been performed according to the FDA guidelines. Sensitive 
methods have been obtained with small sample volume. The accuracy and precision 
results were in agreement with the acceptable ranges. Matrix effect was investigated 
and found to be reduced comparing to other sample preparation methods. Method 
comparison was done with other well established sample preparation techniques.  
 
Further work on MEPS is recommended regarding applying this technique to more 
drugs and their metabolites, exploring other application areas such as environmental 
and food analysis, and modifying the device in a way that can reduce clogging and 
speed up the extraction process.  
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1 INTRODUCTION 
The measurement of drugs and metabolites in biological samples provides information 
that plays an important role in toxicokinetic and pharmacokinetic studies, and in 
therapeutic drug monitoring (TDM). It is often of great importance that results are 
rapidly obtained and that high numbers of samples can be processed (1). Biological 
samples can not usually be assayed directly but require some preparation before 
instrumental analysis. The complexity of the sample preparation procedure needed is 
dependent on the nature of the matrices. Biological fluids such as whole blood, urine and 
plasma are complex and contain a large number of endogenous compounds, some of them 
in high concentrations. The sample preparation procedure should effectively isolate the 
analytes from matrix compounds (2). 
 
Bioanalytical methods are many times used for determination of low concentrations of 
analyte in complex matrices. As a consequence, these methods need to be sensitive, 
precise, selective and robust. The bioanalytical method consists of two main 
components. The first is sample preparation, which consists of the techniques used to 
extract the compounds from the biological fluids such as plasma, serum or urine and 
whole blood before analysis. The second component is detection of the compound, 
often by chromatographic separation from other interfering components left in the 
sample extract. 
 
Recently, developments in the field of bioanalysis have offered new methods for 
sample preparation as well as for chromatographic separation and detection (3). In 
order to process high numbers of samples, techniques allowing for fully automated 
systems are needed. In the following text, a short overview on the sample preparation 
by conventional and newly developed techniques and chromatographic separation and 
detection will be given. 
 
1.1  SAMPLE PREPARATION 
Chromatographic separation and detection techniques often receive the main attention 
in method development. Timewise, however, the sample preparation is a bottle-neck 
and can consume about 80% of the analysis time in some bioanalytical methods (4-5). 
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The need for same-day reporting of results for large numbers of biological samples 
makes high-throughput bioanalysis essential. With the advent of combined liquid 
chromatography-mass spectrometry (LC-MS), which offers possibilities for developing 
high through-put and rapid applications, an increase of attention and focus on sample 
preparation has taken place (4, 6). Sample preparation should be considered as an 
integrated part of the analytical procedure (5). Key features when developing sample 
preparation procedures are automation, integration, on-line and miniaturization (6-7).  
 
New trends in sample preparation have appeared, such as sample preparation in 96-well 
plates and the automation of conventional methods for solid phase extraction (SPE), 
protein precipitation (PP) and liquid-liquid extraction (LLE).  
 
Also more recent approaches are now available such as liquid-liquid microextraction 
(LLME), solid phase microextraction (SPME) and microextraction by packed sorbent 
(MEPS) (4-5).  
 
These new approaches both offer some advantages but also suffer from limitations, 
which explain why the conventional off-line sample preparation methods are still used 
in routine laboratories. 
 
1.2 PROTEIN PRECIPITATION 
Sample preparation by protein precipitation (PP) is often used in combination with LC-
MS in bioanalysis (8). PP can be used to prepare plasma and blood samples. It is a 
simple method based on precipitating the proteins and then analysing the supernatant 
after centrifugation. It can be used both for hydrophobic and hydrophilic compounds. 
Acidic reagents can be used for precipitation, such as trichloroacetic acid and perchloric 
acid. However, these strong acids may cause stability problems for compounds that are 
not stable at low pH. Organic solvents such as methanol, acetone and acetonitrile are 
alternatives to these acids (4, 9-10). Methanol is preferred because it can produce a 
clearer supernatant suitable for direct injection.  
 
Another common type of precipitation for proteins is salt-induced precipitation. As the 
salt concentration of a solution is increased, proteins aggregate and precipitate from the 
solution (11). 
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PP is a rapid and simple sample preparation method, but suffers from the drawback that 
endogenous compounds other than proteins, such as phospholipids, are still present in 
the supernatant, which causes matrix effects in the MS analysis (12). 
 
1.3 LIQUID-LIQUID EXTRACTION 
LLE is a traditional method for sample preparation in bioanalysis (13). The principle 
behind the separation is the distribution of sample components between two immiscible 
liquids (aqueous and organic). The analyte is extracted from the aqueous phase into the 
organic phase. Thereafter, the organic layer is transferred and evaporated. Different 
aspects determine the choice of organic solvents such as: 
• distribution coefficient 
• density difference between liquid phases 
• boiling point, vapor pressure 
• flammability, toxicity 
 
The main advantages of LLE methods are large sample capacity, clean extracts and an 
easy approach to sample concentration. The limitations are: use of environmentally 
harmful organic solvents, time consuming procedure, difficult to automate, risk for 
poor recovery and problems with formation of emulsions. 
 
Traditional LLE has been developed and modified in recent years by introduction of 
liquid phase microextraction (LPME) (14-16), single drop-liquid phase micro 
extraction (LPME) and supported membrane extraction (SME) (4, 17-19). 
 
1.4 SOLID PHASE EXTRACTION 
Solid phase extraction (SPE) was introduced in the early 1970’s and was derived from 
materials developed for reversed-phase chromatography. The principle of SPE is 
similar to LLE in that it is based on the partitioning of the analytes between two phases 
(6, 20). The target analytes should have stronger affinity to the solid phase than the 
matrix components (adsorption step) (6-7). In modern SPE, the sorbent is packed 
between two fritted disks in a polypropylene cartridge and the liquid phase is passed 
through the cartridge (21). SPE cartridges are available in sizes containing 10 mg to 
10g of sorbent. The most commonly used materials are silica-based with chemically 
bonded functional groups or highly cross-linked polymers such as styrene-
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divinylbenzene and polymethacrylate. These cartridges are designed for single use in 
order to eliminate carry-over problems (6).  
 
The principal experimental procedure is the following (4, 6): 
1- Activation the surface of the sorbent by passing of proper solvents (3-5 bed 
volumes) 
2- Application of sample (adsorption step) 
3- Washing to remove unwanted interfering matrix components  
4- Elution of the analytes  
 
There exists a wide range of SPE sorbents such as non-polar, polar and ion exchange. 
This classification is based on the chemical character of the functional group attached 
to the silica. As a consequence, the polarity of the solvent used depends on the chosen 
solid phase sorbent.  
 
For reversed-phase SPE, the stationary phase is usually silica bonded with alkyl and/or 
aryl functional groups. C18 and C8 are the most common sorbents used. The packing 
materials used for SPE and liquid chromatography are similar but particles used in SPE 
are larger (4, 6). Sample preparation by SPE is commonly used in bioanalysis (4, 6, 22). 
It can be performed off-line with automation and on-line integrated with the 
chromatographic system (23-26).  
 
1.5 SOLID PHASE MICROEXTRACTION 
Solid-phase microextraction (SPME) was introduced in the beginning of 1990s by 
Arthur and Pawliszyn (27). This innovative and solvent free technology was developed 
to meet the demand for on-line sample preparation methods (28-30). SPME consists of a 
silica fiber coated with a liquid polymer or a solid sorbent or a combination of both. In 
this technique the coated fiber is exposed to the liquid sample for a specific period of time. 
There are several types of SPME device being used, coated fibers, vessels, steel bars, disks 
and coating on the inside of the tubes. The most popular device is the coated fiber type (4, 
28-32).  
 
SPME has been used in applications for analysis of flavors, fragrances and in the 
forensic field. SPME is usually used together with gas chromatography (GC) (4, 33). 
This technique has some disadvantages such as limited capacity and high cost.  
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1.6 MICROEXTRACTION IN PACKED SYRINGE 
MEPS is a new technique and represents an attempt of SPE miniaturisation using much 
reduced sorbent. It is based on using a syringe with a special needle as an extraction 
device, Figure 1. Sample preparation takes place on the packed bed which can be 
packed or coated to provide selective sampling. MEPS was developed in the 
AstraZeneca research laboratory in Sweden to meet the need for high-throughput 
analysis (34-36). MEPS was first demonstrated in two patents issued 2003 (35-36). The 
first scientific publication appeared in 2004 (34), about using MEPS for determination 
of local anesthetics by using both LC and GC for chromatographic detection. 
 
MEPS can be connected on-line to LC, GC and capillary electrophoresis without 
further modification. In MEPS the sorbent is inserted directly into the needle. The 
MEPS sorbent cartridge can be used for over 100 injections depending on the sample 
matrix. Another important feature is that MEPS can handle sample volumes starting 
from 10 µL and up to 1000 µL.  
 
MEPS can be used both manually and fully automated (the sampling, extraction and 
injection are on-line). 
end plugs
frits
SPE packed
bed
sealing ring
needle
to syringe barrel
 
Figure 1. Schematic picture of a MEPS syringe with integrated sorbent.  
 
The biological fluid is diluted before sample loading. For plasma the dilution factor is 
typically 5, while for whole blood it is typically 25 (37). Thereafter, the sample is 
loaded by withdrawing and ejecting in the sample vial or ejecting to the waste. The 
loading step can be repeated many times to increase recovery of the analyte. Step two is 
the washing of the sorbent, to remove proteins and other unwanted material. The third 
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step is the elution with organic solvent directly to the LC or GC injector, step four. Step 
five is washing A and B and takes place after elution to eliminate the carry-over and 
conditioning the material for further use. Wash A is usually the elution solution and 
wash B is the washing solution used after sample loading, for a schematic presentation 
of the MEPS procedure, see Figure 2.   
 
4x6x 1x 1x 4x
1. Load 2. Wash       3. Elute 4. Inject 5. Wash A     Wash B
 
Figure 2. The five steps involved in the sample preparation by microextraction in packed syringe 
(MEPS). Number of iterations is taken from the protocol used in paper IV. 
 
1.6.1 Operation of MEPS 
In MEPS, multiple sampling can be performed (draw-eject). Recovery from MEPS can 
be affected by different factors, mainly the used sorbent and the influence of number of 
extraction cycles. The extraction recovery of MEPS can be calculated as the following: 
 
Response of extract 
      Recovery = 
Response of direct injection of the same concentration 
× 100 
 
Extraction efficiency can be investigated by number of sample loading needed to reach 
the required sensitivity. During the method development investigation of the number of 
loading cycles that is needed for the required sensitivity should be performed.  
 
Carry-over is an expected problem when using MEPS. This phenomenon can lead to 
bad accuracy and precision (5, 37-38). Carry-over should be estimated for every 
procedure. The degree of carry-over depends partly on the chemical nature of the 
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analyte and can be generated from adsorption in the syringe or generated in the LC 
system. 
 
1.6.2 Application of MEPS 
This technique has been successfully used to extract wide range of drugs and their 
metabolites from different biological matrices such as plasma (34, 38-51), urine (44, 
46, 52-58) and blood (59-62). Other application have been investigated like polycyclic 
aromatic hydrocarbons in water (63), wine (64) and hair (65). MEPS has been 
connected on-line to LC and GC mass spectrometry (5, 34, 37-39, 41-43, 51, 53-54, 
63).  
 
The technique can replace most existing SPE methods by scaling the reagents and 
sample volume. Some review articles are available about MEPS technique discussing 
the factors affecting the performance of MEPS and the recent advances in MEPS (5, 
37-38, 66).  
 
1.7 ANALYTES 
Drug efficacy depends on the concentration of the drug at the site of action. 
Pharmacokinetic studies are designed to determine the fate of the drug in the body 
while pharmacodynamic studies are designed to determine the relation between the 
drug concentration and its effect. Kinetic studies are as rule necessary in order to 
optimize the treatment to reach maximum efficacy and safety. Kinetic and dynamic 
studies are essential to establish therapeutic schedules and to be used for therapeutic 
drug monitoring and dose adjustment. This is important when using drugs with a 
narrow therapeutic window when the relation between plasma concentration and 
therapeutic and or toxic effect has been established. In this thesis different categories of 
compounds were chosen to be a model for MEPS performance evaluation. Developing 
high throughput analysis utilizing small sample volume method for these compounds 
will be of good value in pediatric pharmacokinetic studies and TDM of these 
compounds in children.  
 
1.7.1 Cyclophosphamide  
Cyclophosphamide, an alkylating agent, is widely used as an anticancer and 
immunosuppressive agent, Figure 3. Alkylating agents are the oldest group of cytostatics 
and they are still the corner stone for cancer therapy (67-70). Their use in cancer treatment 
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started in the early 1940’s. Cyclophosphamide is a prodrug that undergoes a complicated 
process of metabolic activation and inactivation. Approximately 70-80% is activated by the 
cytochrome P450 (CYP) enzyme system to form 4-hydroxycyclophosphamide (4-
OHCPA). (69, 71-74). The given doses are between 2-200 mg/day and t½ about 7 hours. 
 
 
 
N
P
O
NHO
Cl
Cl
 
Figure 3. Cyclophosphamide structure.  
 
1.7.2 Anaesthetics 
Local anaesthetics consist of two families: aminoamide and aminoester local 
anaesthetics. They produce profound anaesthesia for several hours.  
 
1.7.2.1 Lidocaine 
Lidocaine (2-(diethylamino)-N-(2,6-dimethylphenyl) ethanamide) was the first member 
of the aminoamide-type local anaesthetics group, Figure 4. It acts by blocking the fast 
voltage gated sodium (Na+) channels in the cell membrane of the neurons, thereby 
blocking the neurotransmission. Lidocaine is applied topically or by local injection, is 
absorbed rapidly and has a rapid onset of action. Approximately 90% of the dose will 
be metabolized in the liver, mainly by CYP1A2 (and to a minor extent by CYP3A4), to 
pharmacologically active metabolites. The t½ of lidocaine is approximately 1.5–2 hours 
(75-77) and the given doses are between 50-300 mg iv.  
 
H
N
O
N
 
 
Figure 4. Lidocaine chemical structure.  
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1.7.2.2 Bupivacaine 
Bupivacaine is another member of the aminoamide type local anaesthetics group, 
Figure 5. It is administered for local anaesthesia including infiltration, nerve block, 
epidural, and intrathecal anaesthesia (76). It is the most toxic among all of the 
anaesthetic drugs. The main use of bupivicaine is to prevent post-operative pain after 
surgical procedures. The given doses are 25-150 mg epidural with t½ between 2.4-3.6 
hours (epidural). 
 
 
N
O
NH
 
Figure 5. Bupivacaine chemical structure  
 
1.7.2.3 Ropivacaine 
Ropivacaine is a local anaesthetic agent which is chemically homologous with 
bupivacaine, Figure 6. Ropivacaine is metabolized by CYP1A2. The elimination half-
life of ropivacaine is 2-6 hours and therefore has a longer duration of action than 
lidocaine. Ropivacaine can also pass the blood-brain barrier and induces toxicity to the 
central nervous system if it reaches the systemic circulation in sufficient concentrations 
(78-81). The given doses are 75-200 mg epidural and t½ 3.6 -6 hours (epidural). 
 
 
 
N
O
H
N
 
Figure 6. Ropivacaine chemical structure  
 
1.7.3 Immunosuppressive drugs 
Immunosuppressive agents are drugs used to suppress the normal activity of the 
immune system (82). They are used to prevent rejection of organs after organ 
transplantation and also in the treatment of autoimmune disorders. The key factor for 
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successful organ transplantation is effective immunosuppressive therapy. The biggest 
challenge for organ transplantation is meeting the need for immunosuppressant to 
prevent rejection, meanwhile minimizing drug-induced toxicities (82-83). 
 
Immunosuppressive treatment of the transplantation patient begins with the induction 
phase, immediately after transplantation maintenance therapy then follows life of the 
allograft. Induction and maintenance strategies include choosing medicines at specific 
doses or at doses adjusted to achieve target therapeutic levels to give the transplantation 
patient long survival. 
 
1.7.3.1 Cyclosporine 
Cyclosporine was introduced to the clinic during the early 1980s, Figure 7. It was the 
first immunosuppressive that was subjected to therapeutic drug monitoring (TDM). 
TDM of cyclosporine is an essential tool in the managements of transplant recipients. 
Cyclosporine displays a large degree of inter-and intra- individual pharmacokinetic 
variability. The given doses range between 1-15 mg/kg/day with t½ between 5-20 
hours. 
 
1.7.3.2 Tacrolimus  
Tacrolimus, Figure 7 is a macrolide antibiotic and its active against helper T cells; 
preventing the production of IL-2 via calcineurin inhibition. This drug is used for 
maintenance immunosuppression and for saving the patients with refractory rejection 
under cyclosporine-based therapy. The given doses between 0.075-0.30 mg/kg/day 
with t½ between 12-16 hours. 
 
1.7.3.3 Sirolimus 
This immunosuppressive agent was approved by the FDA for prevention of kidney 
transplant rejection in 1999, Figure 7. Sirolimus is a macrolide antibiotic that binds to 
the FK-binding protein, its mechanism of action is via the mTOR. It inhibits G1- to S-
phase cell division and, by that, cell proliferation. This agent is used for maintaining 
immunosuppression and to prevent rejection. The given doses are 2-6 mg/day with t½ 
62 hours. 
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1.7.3.4 Everolimus 
Everolimus is a rapamycin analogue, Figure 7. In cancer cells, everolimus inhibits 
mTOR, a protein that acts as a central regulator of tumor cell division, cell metabolism 
and blood vessel growth. Everolimus is a once-daily oral therapy that provides 
continuous inhibition of mTOR. It is used as a complementary immunosuppressant to 
cyclosporine-tacrolimus based protocols in transplant recipients. The given dose is 1.5 
mg/day with t½ of 30 hours. 
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Figure 7. Chemical structures of the immunosuppressive drugs. 
 
1.7.4 Remifentanil 
Remifentanil is a synthetic opioid and a fentanyl analogue, Figure 8. It has 
approximately the same potency as fentanyl but remifentanil has unique 
pharmacokinetic characteristics: a very rapid achievement of the peak effect of an 
intravenous dose, a consistently rapid elimination of the drug with complete cessation 
of its effects within five to ten minutes after discontinuing its administration (84-87). 
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Figure 8. Remifentanil chemical structure  
 
1.8 LIQUID CHROMATOGRAPHY  
The Russian botanist, Mikhail S. Tswett is the father of chromatography and he started his 
pioneer work early 1900s in separating compounds (pigments), extracted from plants by 
using packed columns (88). Tswett used open glass columns with calcium carbonate and 
aluminum particles and noticed different coloured bands and related it to the separation of 
the compounds. The separation technique was named chromatography being obtained from 
the Greek words chroma, (colour) and graph, meaning colour writing (89).  
 
Modern HPLC is considered a further development of Tswetts original chromatographic 
principle. Solvents of different compositions make up the mobile phase, and the particles 
are the stationary phase (90-91). The separation of the compounds is due to partitioning 
between the stationary phase and the mobile phase. It was not until 1970s, that commercial 
liquid chromatography instruments appeared. Before that, different techniques had been 
used e.g. open-column chromatography, paper chromatography, and thin layer 
chromatography. These were only used for qualitative analysis and were suffering from 
lack of separation power between similar compounds.  
By the 1980s, the HPLC technique was well established and is still used for many 
bioanalytical applications. Much advancement in column material and design has taken 
place, and computers and automation were added to the HPLC systems (89, 92). 
 
1.8.1 Ultra performance liquid chromatography 
The underlying principles behind the recent development of “ultra performance” LC 
(UPLC) is based on the van Deemter equation that describes the relationship between the 
flow rate and the theoretical plate height (the height equivalent to a theoretical plate, 
HETP). Since the particle size is one of the variables, using a column with smaller sorbent 
particles will enhance the chromatographic performance. If the particle size decreases to 
less than 2.5 µm, the efficiency will increase substantially even at high flow rate. In 
practice sub 2 µm particle columns are used for this purpose. These columns generate a 
higher back pressure so they must be connected to an instrument that can deliver solvents at 
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the high pressure and at constant flow. Commercial systems are available for UPLC. This 
technique offer shorter analysis time and better sensitivity in addition to increased 
separation power (93-96). 
 
1.8.2 Monolithic columns 
Monolithic columns exhibit high separation efficiency at high flow rate and are not made of 
packed particles. A special feature of monolithic material is the high porosity. This feature 
gives the column the ability for low flow resistance at high speed of the mobile phase, 
which enhances the rate of the mass transfers of the sample molecules through the beds of 
the stationary phase. Monolithic material can be made of both organic and inorganic 
polymers (97).  
 
1.8.3 Detection in chromatography  
1.8.3.1 Photometric detection  
The photometric detector is a common LC detector and measures the amount of light 
absorbed at selected wavelength of the visible or UV region. The main features of this 
detector are universal applicability and easiness of use. Photometric detectors have 
some limitations towards compounds that do not posses a UV chromophore (i.e. 
aromatic rings or double bonds). Lack of selectivity and limited qualitative information 
makes UV-detectors less suitable to use for identification purposes (98). 
 
1.8.3.2 Mass spectrometry detection              
Mass spectrometry is related to gas-phase separation of ionised species according to 
their mass-to charge ratio (m/z) ratio. This type of detection offers high sensitivity and 
selectivity. Mass spectrometry in bioanalysis has progressed dramatically through the 
last twenty years. 
 
The basic components of the mass spectrometer are an inlet device, an ion source, ion 
separation system (mass analyzer) and detector. Electrospray ionisation (ESI) is the 
interface that was used with the equipment for the generation of results for this thesis. 
In the ESI the analyte solution passes through the electrospray needle that is kept at a 
high potential. Charged droplets are sprayed from the needle with surface charge of the 
same polarity equal to the charge on the needle. Droplet formation is assisted by the 
nebulizer gas, usually nitrogen. Also neutral compounds can be transferred to ionic 
form by de-protonation, protonation or cationisation and can thus be analysed by MS 
(99), Figure 9. 
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Figure 9. Diagram of an electrospray ionization source.  
 
There are three steps involved in transferring ions from solution to gas phase 
• Dispersal of fine spray from a region of a strong electrical field  
• Solvent evaporation by heat or dry gas or both  
• Ions evaporating from the surface of the droplet, droplets shrink until they reach 
the level where the surface tension can not stand the charge. At this point the 
droplets disintegrate and produce smaller droplets that can disintegrate further. 
 
The quadrupole mass analyser consists of four parallel rods that have fixed DC and 
alternating RF potentials applied to them. The length and the diameter of the rods 
determine the mass range and the resolution of the equipment. Ions produced in the 
source of the instrument are focused and passed along the middle of the quadrupole 
filter. Their motion will be influenced by the electric field so that only ions with a given 
m/z interval will be in resonance and pass onto the detector. 
 
The selective power of MS can be increased if the quadrupole filters are linked together 
in series, tandem mass spectrometry. (Q1) and (Q3) quadrupoles serve as mass filters, 
while (Q2) quadrupole function as a collision cell where fragmentation by high energy 
collisions take place, Figure 10. The ions passed through Q1 are named precursor (or 
parent) ions. The ions resulted from the fragmentation are called product (or daughter) 
ions (99-101). Selecting a particular ion or ions to monitor will increase the sensitivity; 
this process is called selected reaction monitoring (SRM).  
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Figure 10. A triple quadrupole ESI mass spectrum.  
 
The introduction of MS/MS systems in bioanalytical work started already in the late 1980s 
when flow injection analysis FIA-MS/MS methods were introduced for neonatal screening 
assays (8, 102). Tandem mass spectrometry (MS/MS) is now an established powerful 
analytical technique and it has attained a predominant role over other techniques (100, 
103-104). The combination of LC-MS/MS fulfils most of the analytical needs for 
laboratories involved in laboratory medicine, both in research and routine laboratories. 
Within the last ten years the sensitivity of the instruments has improved significantly. 
This has been possible by optimizing the process of atmospheric pressure ion 
generation and transfer of ions into the high vacuum area of the instrument (105). The 
major innovation was applying the ion spray orthogonal to the main axis of the mass 
spectrometry. 
 
An LC-MS/MS-system offers some advantages over GC-MS in the clinical 
laboratories, since it is applicable also to polar and large molecules. For the routine 
applications in the TDM field, methods for quantification of immunosuppressant drugs, 
the new generation of anticonvulsive and antipsychotic dugs has been developed (8). 
There is an increasing interest to replace existing methods in pharmacology, 
endocrinology and toxicology with LC-MS/MS. However, implementation of LC/MS-
MS methods still require substantial amount of expertise. LC-MS/MS has the potential 
to improve the performance of laboratory medicine and replace the predominant 
methods using immunoassays. This will need full automation and development of high-
throughput applications (8, 102). 
 
Ion source Quadrupole Detector
GAS  (Argon, N2)
 16 
2 AIMS 
The aim of the present work was to explore MEPS as sample preparation method by 
developing on-line and automated quantitative methods for therapeutic drugs that 
combine sample preparation with LC-MS/MS 
More specifically, the aims were: 
 
 Develop a new LC-MS/MS analytical method for cyclophosphamide determination 
in plasma. 
 Develop a new LC-MS/MS analytical method for cyclophosphamide detection in 
whole blood to facilitate in vivo studies. 
 Develop a new LC-MS/MS analytical method for lidocaine, ropivacaine and 
bupivacine detection in whole blood.  
 Develop a new LC-MS/MS analytical method for determination of 
immunosuppressive drugs in whole blood. 
 Develop a new LC-MS/MS analytical method for remifentanil detection in plasma 
to be employed for neonatal clinical studies. 
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3 MATERIAL AND METHODS 
 
3.1 SUBSTANCES 
Study (I) and (II) 
Cyclophosphamide was purchased from Sigma Chemical Company (St. Louis, MO). 
Ifosfamide was used as the internal standard and obtained from ASTA Medica AG 
(Frankfurt, Germany).  
Study (II)  
Lidocaine-d3 (IS) was supplied by Department of Medicinal Chemistry, AstraZeneca, 
Södertälje, Sweden.  
Study (III)  
Lidocaine, ropivacaine, bupivacaine and lidocaine-d3 (IS) were supplied by the 
Department of Medicinal Chemistry, AstraZeneca (Södertälje, Sweden). 
Study (IV) 
Cyclosporine and everolimus were provided by Novartis (Basel, Switzerland) and 
everolimus also purchased from Fluka, sirolimus was provided by Wyeth (Madison, 
NJ), tacrolimus was provided by Astellas Pharma Inc (Tokyo, Japan). The internal 
standards ascomycin (ASC) and cyclosporine D (CYD) were purchased from Alexis 
Biochemicals (San Diego, CA). 
Study (V) 
Remifentanil hydrochloride and the internal standard remifentanil-13C6 hydrochloride 
(IS) were purchased from Toronto Research Chemicals (North York, Canada). 
 
3.2 REAGENTS  
All substances and chemicals were of analytical grade except for, methanol and 
ammonium formate in study (IV) which were of LC-MS grade. The water used in the 
analysis for all the studies was Reagent Grade Milli-Q Plus water (Millipore Co, 
Bedford, MA). 
 
3.3 BIOLOGICAL SAMPLES  
Study (I)  
Blank human plasma was obtained from AstraZeneca blood bank. Patient samples were 
obtained from patients who had been subjected to allogenic bone marrow 
transplantation at Karolinska Huddinge hospital.  
 18 
Study (II) 
Blank mouse blood was obtained from AstraZeneca, Södertälje  
Study (III) 
Blank human blood was obtained from AstraZeneca blood bank. 
Study (IV) 
Blank human blood used for calibration and controls were purchased from the 
Karolinska University Hospital blood bank. Patient samples were obtained from 
decoded left-over patient blood samples from the TDM service at the Clinical 
Pharmacology Department.  
Study (V) 
Blank plasma was obtained from Karolinska University Hospital blood bank. 
Patient samples used for method comparison were decoded left-over patient blood 
samples from the TDM service at the Clinical Pharmacology Department.  
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3.4 SAMPLE PREPARATION  
The MEPS conditions for different analytes and matrices (human plasma in study I and 
V; mouse blood in study II and human blood in study III and IV) were optimized to the 
protocols presented below. In all studies, the MEPS was handled by a CTC-PAL 
autosampler. All new MEPS cartridges were manually activated and equilibrated with 
50 μL methanol followed by 50 μL of water before being used. A compilation of the 
MEPS approaches is found in Table 1. 
 
Table 1. Compilation of the MEPS protocols used in Study I-IV 
Study  Compound type Analyte  Matrix/ 
dilution 
factor 
Sorbent Sampling 
vol;  
No of 
sample 
loadings 
Wash/ 
equilibration 
steps n/n 
Samples/ 
cartridge 
I 
 
Cytostatic Cyclophosphamide Plasma/5 C2  25 µL;1 4/4 100-150 
II Cytostatic Cyclophosphamide Blood/25 C2 100 µL;4 4/4 40-100 
III Local anaesthetics Lidocaine, 
Ropivacaine 
Bupivacaine 
Blood/25 C18 100 µL;3 3/3 ~50 
IV Immunosuppressive Cyclosporine, 
Everolimus, 
Sirolimus 
Tacrolimus 
Blood/25 C8 100 µL;6 4/4 100-120 
V Anaesthetics Remifentanil Plasma/9 M1(mixed 
mode) 
50 µL;4 4/4 ~50 
 
3.5 INSTRUMENTS AND MATERIAL 
Study I  
MEPS-LC-MS/MS: Zorbax (SB-C8, 50×2.1mm, 3.5µm) column obtained from 
Agilent (Santa Clara, CA) was used with Gradient HPLC system. 
Triple quadrupole mass spectrometric instrument Micromass QII-spray (Waters 
Corporation, Manchester, UK) equipped with a Z-electrospray interface operated in 
positive ion mode. 
LLE-LC-UV: HPLC isocratic mode was used, using Phenomenex LC column, polar-
RP 80A (3.0 ×150 mm, 4µm).  
The detector was Milton Roy Spectro Monitor 3100 (Ivyland, PA) and the UV 
detection wavelength was 195 nm. 
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Study II 
Ace C18 (100×2.1 mm, 3µm) column obtained from Advanced Technologies 
(Aberdeen, Scotland) was used with HPLC gradient mode. 
Triple quadrupole mass spectrometric instrument Micromass QII-spray (Waters 
Corporation, Manchester, UK) equipped with a Z-electrospray interface operated in 
positive ion mode was used. 
 
Study III 
Gradient HPLC mode was used using Zorbax SB-C8 (50×2.1mm, 3.5µm) column 
obtained from Agilent (Santa Clara, CA). 
Triple quadrupole mass spectrometric instrument Micromass QII-spray (Waters 
Corporation, Manchester, UK) equipped with a Z-electrospray interface operated in 
positive ion mode. 
 
Study IV and V 
Kinetex C18 column (50×2.1mm, 2.6µm) obtained from Phenomenex (Torrance, CA) 
was used as analytical column; Hypersil Gold C8 (10×2.1 mm) obtained from Thermo 
Scientific was used as guard column with gradient HPLC system. 
Triple quadrupole mass spectrometer (TSQ Quantum, Thermo Scientific, Waltham, 
MA) equipped with electrospray ionisation source (ESI). 
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4 RESULTS 
 
4.1 DESIGN AND METHOD DEVELOPMENT 
4.1.1 Study I 
Rapid and Sensitive Method for Determination of Cyclophosphamide in Patients 
Plasma Samples Utilizing Microextraction by Packed Sorbent Online with Liquid 
Chromatography-Tandem Mass Spectrometry (MEPS LC-MS/MS) 
 
A MEPS procedure for cyclophosphamide quantification in plasma was developed by 
testing different sorbents, C2, C8, C18 and polystyrene. The highest recovery was 
obtained with C2, when plasma sample was diluted four times with water. Washing 
solution volume was optimized. 30 µL of 95:5 methanol - water was used to elute 
cyclophosphamide. Ifosphamide was used as internal standard since it is a 
cyclophosphamide structural isomer. LLE-HPLC-UV was used as reference method.  
The analysis was based on a C8 analytical column. Cyclophosphamide and the internal 
standard were co-eluted and no cross-talk was observed between the SRM channels. 
The retention time for cyclophosphamide was 4.45 min with a total analysis time of 5.0 
min. Detection and quantification was performed using SRM.  
 
LLE-HPLC-UV 
This reference method was based on previous published methods utilizing LC-UV with 
modification of the mobile phase and the column (106-107). Different types of C8 
columns were tested for better separation. Liquid extraction was used for sample 
preparation. The sample preparation time was 45 min. The retention time for 
cyclophosphamide using this method was 16.5 min. The analysis time was 30 min, this 
was due to the presence of a peak eluting after cyclophosphamide.  
 
4.1.2 Study II 
On-Line Determination of Cyclophosphamide in Blood Samples Utilizing 
Microextraction by Packed Sorbent and Liquid Chromatography Tandem Mass 
Spectrometry (MEPS-LC-MS/MS). 
 
A prerequisite for method development was the possibility to use 20 µL blood for 
sample analysis in order to facilitate pharmacokinetic experiments in mouse by using 
serial tail sampling. 
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Based on the previous study, MEPS-C2 sorbent was chosen for cyclophosphamide 
quantification in the diluted blood, with a dilution factor of 25. The IS was 2H3-
lidocaine. Pumping the sample 4×100 µL was enough to gain the required sensitivity. 
The carry-over was eliminated by four washing cycles of both the elution solution 
followed by the washing solution. Gradient HPLC was used. The scan mode was SRM 
using the proton adduct as precursor ion [M+H]+. 
 
4.1.3 Study III 
Microextraction by packed sorbent for LC–MS/MS determination of drugs in 
whole blood samples. 
 
Local anaesthetics in this study were quantified from whole blood samples. The method 
was developed to handle small sample volumes. In the study MEPS-C18 was used to 
extract the local anaesthetic compounds from whole blood while C8 guard and 
analytical columns were used. Only water was used for washing to prevent analyte 
leakage. Due to the basic nature of the analytes the elution solution was methanol- 
water containing 0.25% ammonium hydroxide. Three washing cycles of elution and 
washing solution were capable of reducing the carry-over to 0.02%. The packing bed 
was using for about 50 samples before it was discarded. The scan mode was SRM 
using the proton adduct as precursor ion [M+H]+. 
 
4.1.4 Study IV 
Determination of four immunosuppressive drugs in whole blood using MEPS and 
LC-MS/MS allowing automated sample work-up and analysis. 
 
The chromatographic system was based on a 50 mm reversed-phase C18 column and 
used a gradient of methanol: 0.1% formic acid from 43% to 98% in 2.5 min. A C8 
guard column was used to protect the chromatographic column and did not prolong 
retention. In this system, which was developed to obtain a shorter time of analysis, the 
analytes and internal standards were not fully separated. The first eluting substance was 
ASC (1.60 min), which was used as internal standard for EVE, SIR and TAC. These 
eluted within 0.1 min after ASC and overlapped chromatographically. CYS eluted 
slightly before its internal standard CYD and these also overlapped 
chromatographically.  
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Detection and quantification was performed using the SRM, selective detection was 
achieved in the mass spectrometer by detecting products ions formed from the 
ammoniated molecules. No signs of interference due to cross-talk between the SRM 
channels were observed. Formic acid and ammonium formate were added to both 
mobile phase A and B and the concentrations were optimized for sensitivity and 
chromatographic performance. 
The MEPS procedure was developed by manual operation and was then transferred to 
the CTC-PAL platform. 
 
4.1.5 Study V 
Determination of remifentanil in human plasma by liquid chromatography and 
tandem spectrometry utilizing micro extraction in packed syringe (MEPS) as 
sample preparation  
 
MEPS was used to quantify remifentanil in whole plasma utilizing only 20 µL. For 
development of the MEPS procedure a generic SPE protocol for basic compound 
extraction was followed using different sorbent materials. Different percentages of 
methanol were tested for washing and elution to obtain the highest recovery. The 
different sorbents tested were C2, C4, C8, C18 and M1 (mixed C8 and cation 
exchange). The highest recovery was obtained with M1 sorbent, Figure 11. The method 
development was done manually using spiked plasma with 20 ng/mL of remifentanil.  
 
Remifentanil-13C6 was available commercially and chosen as internal standard to 
provide best possible quantification. A reversed-phase chromatographic system was 
selected using a Kinetex C18 column in order to achieve a rapid analysis time and a 
low back pressure.  
 
The mass spectrometric detection was performed with SRM in order to achieve high 
selectivity and sensitivity. Monitoring conditions were optimized for remifentanil and 
the IS. Positive electrospray ionisation was chosen, which gave the protonated 
molecules as major species and these were selected as precursor ions. A number of 
intense product ions were observed.  
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Figure 11. Comparison between different MEPS sorbents on the recovery (%) of remifentanil. 
 
4.2 METHOD VALIDATION  
4.2.1 Linearity  
For all studies linearity was assessed by calibration curves generated from several 
concentration levels for each analyte. The calibration curve was constructed by linear 
regression of the analyte/IS peak area ratio against the concentration. The calibration 
curve used 1/x2 as weighing factor. The validation results of the linearity for all the 
studied analytes are listed in Table 2. 
 
Table 2. Summary of the linearity results for all the studied analytes. 
 
Analyte Unit Linearity range r2 
CPA plasma µg/mL 0.50-150 0.999, n=6 
CPA blood µg/mL 0.10-100 >0.99, n=3 
Lidocaine nmol/L 10-10 000 0.996, n=3 
Ropivacaine nmol/L 10-10 000 0.999, n=3 
Bupivacaine nmol/L 10-10 000 0.995, n=3 
CYS ng/L 3-1500 0.999, n=6 
EVE ng/L 0.5-50 0.998, n=6 
SIR ng/L 0.5-50 0.994, n=6 
TAC ng/L 0.5-50 0.993, n=6 
Remifentanil ng/L 0.05-50 0.999, n=6 
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4.2.2 Accuracy and precision  
Accuracy and precision were studied by running three or four levels of QC samples 
with replicates for each concentration during several days. Each day new calibration 
curve was prepared. The accuracy and precision results are summarised for all the 
analytes in Table 3. 
 
Table 3. Summary of accuracy and precision results for all the studied analytes. 
Accuracy 
range  
Precision, CV% range Study  Analyte  
 Intra-day  
(n=6), % 
 
Inter-day 
 (n=18), % 
 
I Cyclophosphamide 
in plasma 
95-106 1.0-5.0 5.0-9.0 
II Cyclophosphamide 
in blood 
102-110 2.0-7.0 4.0-6.0 
III Lidocaine 
 
90-109 1.0-3.0 2.0-7.0 
III Ropivacaine 
 
85-97 1.0-3.0 2.0-12.0 
III Bupivacaine 
 
89-97 2.0-5.0 5.0-12.0 
IV Cyclosporine  
 
102-103 4.2-6.2 5.1-7.1 
IV Tacrolimus 
 
103-106 2.0-8.4 7.4-9.1 
IV  Sirolimus 
 
102-108 3.8-5.0 6.8-8.9 
IV Everolimus 
 
103-109 3.5-11.7 6.3-13.7 
V Remifentanil  
 
97.8-102 4.4-6.3 6.3-11.3 
 
 
4.2.3 Limit of detection and quantification  
Lowest limit of quantification (LLOQ) was defined as the lowest point in the standard 
curve with precision not exceeding 20%. Limit of detection (LOD) was estimated at a 
signal to noise ratio of 3. This concentration was reached by dilution the lowest point of 
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the standard curve with blank plasma. Limit of detection and quantification for all the 
analytes are summarised in Table 4. 
 
Table 4. Summary of the LOD and LOQ results for all the studied analytes 
Study Number Analyte  LOD LOQ 
I Cyclophosphamide in 
plasma µg/mL 
0.005 0.50 
II Cyclophosphamide in 
blood µg/mL 
0.005 0.10 
III Lidocaine, nmol/ 
 
3.5 10.0 
III Ropivacaine, nmol/l 
 
3.5 10.0 
III Bupivacaine, nmol/l 
 
3.5 10.0 
IV Cyclosporine, ng/ml 
 
0.9 3.00 
IV Tacrolimus, ng/ml 
 
0.15 0.50 
IV Sirolimus, ng/ml 
 
0.15 0.50 
IV Everolimus, ng/ml 
 
0.15 0.50 
V Remifentanil, ng/ml 
 
0.02 0.05 
 
 
4.2.4 Selectivity 
Using MEPS as sample preparation provided selective methods, in study I, II and III 
selectivity was investigated by analysing different blank blood samples with and 
without adding IS. LC-MS/MS analysis showed no interferences from endogenous 
compounds, see Figure 12. In study IV the selectivity was studied by running three 
different blank samples while monitoring the transitions for the four analytes moreover 
for each of the analyte, 20 blood samples from patients not receiving the respective 
drug were analysed for interfering peaks. No interferences were detected. Also in study 
V the selectivity was tested by analysing 20 randomly selected patient samples from 
TDM laboratory for patients treated with antiepileptic drugs.  
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Fig 12. Representative chromatograms with mass spectrometric detection obtained from blank blood 
sample (left) and from human blood spiked with lidocaine, ropivacaine, bupivacaine (750 nmol/L each) 
and IS (right). 
 
4.2.5 Matrix effect 
Two approaches were followed to investigate the matrix effect; post column infusion 
and post-extraction spike methods in study IV (Figure 13) and study V (Figure 14). No 
significant matrix effect was observed at the retention time of the analytes. In study II 
no significant matrix effect (ion suppression) at cyclophosphamide retention time was 
observed through post column infusion experiment. 
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Figure 13. Matrix effect after injecting a blank blood extract for study IV. The analytes were infused post 
column at a flow rate of 10 µL/min. For comparison the retention time of the analytes are shown in the 
lower traces. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14. Results from post column infusion experiment in study V. 
 
4.2.6 Carry-over 
Carry-over was investigated by running a blank sample or elution solution after the 
highest standard concentration. The carry-over was reduced by washing the sorbent a 
number of times with washing solution followed by elution solution. The measured 
carry-over was between 0.02-0.40% among all the investigated analytes. 
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4.2.7 Method comparison and application of the methods 
In study I method comparison was made between MEPS-LC-MS/MS and LC-UV for 
cyclophosphamide determination in plasma (Figure 15). 170 patient samples were 
analysed by both methods with mean ratio between 1.02±0.11 ranges from 0.81-1.19.  
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Figure 15. The ratio of patient plasma concentrations obtained by LC-MS/MS / LC-UV plotted against 
concentrations obtained using LC-MS/MS. 
 
In study IV, method comparison was done between MEPS-LC-MS/MS, protein 
precipitation LC-MS/MS and immunoassay methods. The ratio (immunoassay/MEPS) 
were as the following: 
 
CYS: 1.24±0.41 (r2 =0.97, n=20), EVE: 1.48± 0.23(r2 =0.84, n=20), SIR: 0.97± 0.11 (r2 
=0.98, n=20) and TAC: 1.36 ± 0.41 (r2 =0.95, n=20). 
 
The comparison for MEPS-LC-MS/MS and protein precipitation LC-MS/MS showed 
that the new MEPS method results were in agreement with protein precipitation LC-
MS/MS (Figure 16). 
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Figure 16. Method comparison between MEPS and the reference method protein precipitation (n=20 for 
each). 
 
4.2.8 Extraction recovery and extraction efficiency 
Extraction recovery for MEPS in study II and III was calculated by comparing the peak 
area of extracted QC samples (low and high) with peak area obtained from standards 
prepared in mobile phase, this experiment was done off-line. The extraction recovery 
was over 90% (Figure17). 
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Figure 17. Comparison of mass chromatogram of lidocaine (1000nmol/l), ropivacaine (500 nmol/l) and 
bupivacaine (500nmol/l) obtained by direct injection (in the mobile phase, top) and after extraction from 
blood with MEPS (below). 
 
Extraction efficiency was evaluated in study IV and V by testing multiple loading 
cycles (1-10) on the highest standard concentration sample, using new sample for each 
testing loading cycle, this experiment was done off-line. In study IV six sample 
loadings were satisfactory for the needed sensitivity (Figure 18), while in study V, four 
sample loadings were needed to get sufficient sensitivity (Figure 19).  
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Figure 18:.Tacrolimus response (as peak area) as a function of the number of MEPS extraction cycles. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 19. Remifentanil mass spectrometry response (peak area) as a function of the number of MEPS 
loading cycles. 
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5 DISCUSSION 
In bioanalysis, a large fraction of the total analysis time is related to the sample 
preparation step. Therefore there is a need for new sample preparation techniques that 
will enable time effective high throughput analytical methods to be developed. The 
general aim of this work was to investigate and evaluate MEPS as new on-line sample 
preparation technique by developing new analytical methods for different categories of 
compounds utilizing MEPS in combination with LC-MS/MS. It has been proposed that 
MEPS has some potential advantages such as reducing the matrix effect, reducing the 
quantity of used solvents, reducing sample volume, enabling automation and 
standardization techniques that simplify method development (3, 36-37). This work 
confirmed that MEPS is a useful sample preparation technique for bioanalysis in 
combination with LC-MS/MS. 
 
5.1 EVALUATION OF THE PERFORMED STUDIES   
In study I and II, methods for determination of cyclophosphamide were developed for 
human plasma and mouse blood. The method for human plasma was used for the 
analysis of a large number of patient samples demonstrating the capability of using 
MEPS for automation. The accuracy of the results was confirmed by comparison with 
an established reference method. The MEPS LC-MS/MS method had higher sensitivity 
and used a reduced sample volume. 
 
For determination of cyclophosphamide in mouse blood the MEPS procedures were 
slightly modified. A smaller sample volume was used (20 µL instead of 50 µL) in 
combination with a five times higher dilution before loading. This was needed to avoid 
clogging of the cartridge. Another modification was the elution solution to provide a 
stronger response. The method of study II was used to study different blood sampling 
techniques for pharmacokinetics studies in mice (108), animal models provide basic 
knowledge about the biochemical fate of drug biotransformation and it is a relevant 
physiological system for evaluation of drug metabolism (109). Mice are the species of 
choice for toxicological evaluation (110). Usually large number of mice is needed for 
kinetic studies since samples at many time points are needed and also relatively large 
blood volumes. Reducing the number of mice needed is possible by changing the 
traditional blood sampling procedure, from retro-orbital sinus to tail vein bleeding 
technique. The main limitation of using mice is that only small blood volume can be 
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obtained at each sampling point, so the development of sensitive analytical methods 
that require small blood volume is of great value to facilitate pharmacokinetics studies 
(111).  
 
In study III three local anaesthetics were determined in human blood. The study further 
explored the potential of MEPS utilizing blood as specimen. The procedure used 25 µL 
of blood and the validation demonstrated that a well functioning and automated method 
for determination of lidocaine, bupivacaine and ropivacaine was successfully 
developed. 
 
In study IV the MEPS-LC-MS/MS technique was used for determination of four 
immunosuppressive drugs in whole blood. These drugs are commonly monitored in 
different clinical laboratories using immunoassays, but these methods suffered from 
lack of specificity of certain test systems results in a method deviation (bias) (84). 
There are an increasing number of laboratories, who have switched to LC-MS/MS, for 
immunosuppressant quantification. This is an important application in the field of TDM 
with a high demand on sample throughput. TDM needs to deliver a precise and 
accurate measurement of an administrated drug to be a successful tool (112). Our 
method was compared with both immunochemical methods and a LC-MS/MS 
procedure based on PP as sample preparation method. The accuracy of the MEPS 
method was confirmed by acceptable agreement with the reference method. The 
difference to immunochemical method was confirmed in previous work (113). The 
benefit of using MEPS for routine determination of immunosuppressive drugs with LC-
MS/MS is the possibility of automation besides a cleaner extract. This method is ready 
to be used as a new analytical platform for TDM in clinical routine environment.  
 
Study V was specifically aimed at reducing the sample volume for determination of 
remifentanil in plasma from newborns. The sample volume was successfully reduced 
from 50 µL (using PP) to 20 µL, which is a significant difference. The limited total 
blood volume that can be taken is one of the biggest practical limitations in clinical 
pharmacokinetics studies on infants and children (114). For pediatric patients, the 
quantity of the withdrawn blood is limited by patient's age, size and underlying 
diseases. This is emphasis the necessity for developing accurate analytical methods that 
can handle small sample volume (115-116). 
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5.2 MATRIX EFFECT AND AUTOMATION USING MEPS 
 Influence from matrix is common in ESI-LC-MS method since interfering compounds 
might co-elute with the analytes. Other ionisation techniques used in LC-MS also suffer 
from matrix effects but to lesser extent (117-118). Matrix effects seen in LC-MS are 
related to the competition of charges between the analyte and co-eluting interfering 
substances, which will affect the efficiency analyte ionisation (119-121).  
 
Problems with matrix effect are common when using PP as sample preparation method. 
Sample preparation with PP is common in LC-MS methods. This is due to the high 
selectivity of the detection that allows PP procedures to be used for many applications 
(12, 90, 95). In previous publications, the MEPS technique was demonstrated to reduce 
salt and phospholipid concentrations significantly compared to PP (37-38). In study IV 
and V the matrix effect was investigated. Two approaches were used to assess the 
matrix effect; qualitative and quantitative. The qualitative approach consists of post-
column infusion, in which the analyte is constantly infused after the analytical column, 
while injecting a blank matrix extract (122). In the quantitative approach the response 
of the analyte in a reference solution (mobile phase) is compared to the response of the 
analyte spiked into a blank matrix extract (38, 123). The results from study IV and V 
confirmed that MEPS reduces the influence from matrix as compared with PP. 
 
A key feature of MEPS is the possibility of automation, which is more difficult when 
using SPE. This is due to the larger elution volumes usually needed necessitating a 
concentration step. The automation of SPE is possible by using special pipetting robots 
or by using switching valves (6) In MEPS the syringe is used both for extraction and 
injection. The direct injection of the eluent is possible because of the limited elution 
volume needed.  
 
The potential of fully automated systems makes MEPS an attractive method in 
combination with LC-MS/MS. By using the highly selective LC-MS/MS technique, the 
full chromatographic separation of analytes is not required and thus gives shorter 
analysis times. Automation of the entire analytical system is essential for developing 
LC-MS/MS to make it competitive with immunoassay analyzers commonly used in 
clinical chemistry and medical laboratory.  
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5.3 FACTORS AFFECTING MEPS PERFORMANCE 
Composition of the washing solution 
The role of the washing solution in MEPS is the same as in SPE to selectively remove 
the interferences from the sorbent while retaining the analytes. In method development 
the washing step should be designed to avoid more than a 5% analyte loss. Following 
this rule, in study I, II and IV the washing solution consisted of 95:5% (water: methanol), 
while in study III only water was used as washing solution. The type of interaction 
between the analyte and the sorbent is mainly based on hydrophobic. A better cleaning 
can be obtained by repetitive washings but this will prolong the time needed for the 
procedure and may increase the risk for leakage (38). The design of the washing 
procedure is a trade-off between recovery and degree of washing (38).  
 
In study V where mixed mode sorbent was used the washing solution consisted of 5% 
methanol in aqueous 0.1% formic acid in order to retain remifentanil on the ion 
exchange functionality.  
 
MEPS and carry-over  
Carry-over is expected to occur when using MEPS and must always be considered. 
This phenomenon depends on several factors such as used sorbent, the type of 
interaction between the analyte and the sorbent, design of the procedure and the design 
of the hardware.  
 
In study IV and V the carry-over was tested by running blank samples after the highest 
standard concentration, while in study I, II and III the carry-over was tested by running 
elution solution after the highest standard concentration. In all the five studies the level 
of carry-over (<0.4%) was less that 0.5% which is the maximum carry-over proposed 
for automated systems (124). 
 
Carry-over related to MEPS can vary between applications (37). MEPS has a small 
quantity of sorbent, which can be easily and effectively washed online while the 
previous sample is still running. The between sample washing procedure must be 
optimized with regard to carry-over. Usually the elution solution is sufficient for 
washing. It is rather the number of washing cycles that are optimized during the method 
development. In the present studies the numbers of washing cycles were 3 or 4. In 
addition to washing the sorbent also the injector must be cleaned between injections.  
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Also there are some approaches to reduce carry-over by better design of the MEPS 
syringe. One of the approaches is that the sample is no longer in contact with the 
syringe but it is aspirated into a holding loop. The syringe only acts as an aspirator and 
dispenser.  
 
Extraction efficiency 
In study IV and V the effect of sample loading replicates on the extraction efficiency 
was investigated (Figure18). There was increase in amount of extracted analyte 
response (peak area) when increasing the number loading replications.  
 
The time for interaction between the sorbent and the sample is critical so the speed of 
sample loading should be considered. Method developing procedures was done 
manually for all the studies. A slight variation within the results was noticed due to 
operator performance since it is difficult to maintain the same speed of sample loading. 
A hand-held automated analytical syringe will help to overcome this problem and has 
been presented by SGE.  
 
The elution solution 
Since small amount of sorbent is used in MEPS, the elution step can be achieved by 
using a small volume of elution solution which can be injected directly into the 
chromatograph. The elution solution must be able to displace the analytes from the 
sorbent with maximum 50 μL volume. For MEPS methanol is a common organic 
modifier (37). In study III where the analyte was a weak base a mixture of methanol 
and water was used containing 0.25% ammonium hydroxide as elution solution. This 
solution was capable to break the nonpolar interaction between the analyte and the 
sorbent. In study V where the type of interaction is ionic, the pH should be two units 
above the pka value. For this purpose the solution consisted of methanol and water 
90:10 (v/v) containing 3% ammonium hydroxide.   
 
MEPS sorbents 
Sorbents used in MEPS are the same as in SPE so many of the existing SPE methods 
can be replaced by rescaling and modification.  
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In paper I and II, C2 was chosen for cyclophosphamide analysis since it gave the 
highest recovery. This might be due to the fact that the C2 sorbent is the most polar 
among the tested sorbents (C18, C8 and C4) and that the analyte is slightly polar and 
more easily desorbed. In paper IV, C8 sorbent was chosen for immunosuppressive 
quantification as it produced the highest recovery among the tested sorbents (C18, C8, 
C4 and C2). In paper V where the analyte is basic, mixed mode sorbent was used 
(cation exchange, C8) for remifentanil quantification. This choice was made after 
testing different sorbents. The mixed mode sorbent is believed to produce cleaner 
extracts.  
 
Through this work it was noticed that the performances of MEPS cartridge was affected 
by the number of processed samples. This was noticed especially in low concentration 
samples. In study IV two types of C8 sorbents were used. One was the commercially 
available C8 and the other was modified C8 sorbent with wider needle to reduce the 
back pressure. This needle type reduced clogging and resulted in a prolonged the life 
time of the sorbent, making it possible to inject 120 blood samples before replacement. 
For plasma samples, MEPS sorbent can be used for up to 120 samples.  
 
5.4 MEPS AND INVESTIGATED APPLICATIONS 
Cyclophosphamide 
There are several publications about cyclophosphamide quantification utilizing LC-
MS/MS, LC-UV and GC-MS with different adopted sample preparation methods (68, 
125-131). A comparison among these methods is summarized in Table 5. In this study 
we presented for the first time on-line sample preparation method for 
cyclophosphamide quantification that utilize only 50 µL sample volume which is 
considered to be the smallest sample volume among other published methods. Study II 
is the first published method for cyclophosphamide quantification in blood.  
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Table 5. Comparison between several cyclophosphamide measuring methods  
 
Analysis 
method 
Extraction 
method/ 
sample 
volume 
Matrix Extraction 
time 
(min) 
Analysis 
time 
(min) 
Limit of 
detection
ng/mL 
Method ref 
LC-
MS/MS 
MEPS 
(50 µL) 
mouse 
plasma  
1 4.5 5.0 Study I 
LC-
MS/MS 
PP  
(250 µL) 
mouse 
plasma  
35 2.0 3.1 (126) 
LC-
MS/MS 
PP  
(100 µL) 
human 
plasma  
20 10.0 20.0 (129) 
LC-
MS/MS 
SPE  
(450 µL) 
human 
plasma  
20 9,2 15.0 (128) 
 
Local anaesthetics in whole blood  
Local anaesthetics have been quantified in urine, serum and plasma (56, 76, 78, 132-
142). This is the first method to quantify local anaesthetics in blood. Good sensitivity 
was obtained with 25 µL sample volume needed. The sample preparation was simple 
and automated. Mass spectrometry was first used for local anaesthetics determination in 
2000 (42). SPE was used as sample preparation in some of the methods (140, 143). 
These methods require large sample volume and the procedures were done off-line.  
 
Immunosuppressive in whole blood 
LC-MS/MS has been used for detection of immunosuppressive drugs in whole blood 
with different methods of sample preparation (12, 82, 112, 144-155). Quantification of 
immunosuppressant is recommended to be in whole blood (156) due to the large 
distribution in erythrocytes; 95% for TAC (157) and SIR (158), between 40-60% for 
CYS (159) and about 75% for EVE (160). Most published sample preparation methods 
are PP and SPE. The main advantages for using MEPS in immunosuppressive 
quantification are; fully automated system, highly sensitive method using only 50 µL 
sample volume. Also cleaner extracts can be obtained with MEPS which is a benefit in 
a routine laboratory. 
 
Remifentanil 
Bioanalysis of remifentanil is challenging, since remifentanil is subjected to hydrolysis 
catalyzed by tissue and circulating esterases (84-86, 161). Several methods have been 
published for remifentanil quantification in whole blood (162-167) (162, 168-170) and 
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plasma (171-172) LLE sample preparation method was mainly used in the previous 
methods. LLE method required long time working procedure besides using large 
quantity of solvents moreover, these procedures were not automated. Also solid phase 
extraction was used either as main sample preparation method or after using PP. Those 
methods required 250-500 µL sample volume and the procedures were performed 
offline. By using MEPS as sample preparation method, sample volume needed was 
only 20 µL and high sensitivity achieved with total analysis time of five minutes with 
automated sample preparation procedures. 
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6 CONCLUSION  
An increasing interest in sample preparation has been generated by introducing new 
extraction techniques that addressed the need for automation and miniaturization. 
Microextraction by packed syringe MEPS is a promising sampling technique especially 
when used combined with LC-MS/MS. 
• The procedures were fully automated with processing time as low as one min 
per sample (study I). 
• In application to blood samples, the sorbent could be used for more than one 
hundred samples before the extraction recovery was reduced. 
• The MEPS technique can be used for a wide range of compounds and requires a 
small sample volume. In addition, less amount of solvent is needed than for 
traditional SPE. 
• MEPS can be applied to many of the of the existing SPE methods. 
• The use of MEPS is effective to reduce the matrix effect and thus provide more 
precise and accurate methods 
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7 FUTURE PERSPECTIVES  
Developing of sample preparation in term of miniaturization, automation and 
introduction of new selective solid phase will continue. Future work should be focused 
on applying this technique to other drugs and their metabolites. Exploring a new range 
of applications in different areas such as environmental and food analysis will add new 
applications to this technique abilities. 
 
Using MEPS with sorbents such as antibodies and molecularly imprinted polymers 
(MIPs) can potentially increase selectivity.  
 
Better design of the extraction device will facilitate sampling, separation and 
quantification. In this thesis we have used modified hardware in term of wider needle. 
Further work should be done to enhance the MEPS performance by trying to reduce the 
back pressure and thus prevent clogging. Also the autosampler that is used with MEPS 
should be modified in term of the used software and the applied washing mechanism. 
Modifying the software will speed up the extraction process and thus more throughput 
analysis can be obtained and by working on the washing procedures carry-over 
problem can be eliminated. 
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